{"id":19066,"date":"2022-10-24T18:02:13","date_gmt":"2022-10-24T21:02:13","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/"},"modified":"2022-10-24T18:02:13","modified_gmt":"2022-10-24T21:02:13","slug":"c1071005-mieloma-multiplo","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/","title":{"rendered":"C1071005 Mieloma m\u00faltiplo"},"content":{"rendered":"<p><strong>C1071005<\/strong><\/p>\n<p>Estudo de fase 3, randomizado, multic\u00eantrico, de 3 bra\u00e7os, aberto para avaliar a efic\u00e1cia e a seguran\u00e7a de monoterapia com elranatamabe (pf-06863135) e elranatamabe + daratumumabe versus daratumumabe + pomalidomida + dexametasona em participantes com mieloma m\u00faltiplo reincidente \/ refrat\u00e1rio que receberam pelo menos 2 linhas de terapia anteriores incluindo lenalidomida e um inibidor de proteassoma.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>C1071005 Estudo de fase 3, randomizado, multic\u00eantrico, de 3 bra\u00e7os, aberto para avaliar a efic\u00e1cia e a seguran\u00e7a de monoterapia com elranatamabe (pf-06863135) e elranatamabe + daratumumabe versus daratumumabe + pomalidomida + dexametasona em participantes com mieloma m\u00faltiplo reincidente \/ refrat\u00e1rio que receberam pelo menos 2 linhas de terapia anteriores incluindo lenalidomida e um inibidor [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19066","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>C1071005 Mieloma m\u00faltiplo - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C1071005 Mieloma m\u00faltiplo - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"C1071005 Estudo de fase 3, randomizado, multic\u00eantrico, de 3 bra\u00e7os, aberto para avaliar a efic\u00e1cia e a seguran\u00e7a de monoterapia com elranatamabe (pf-06863135) e elranatamabe + daratumumabe versus daratumumabe + pomalidomida + dexametasona em participantes com mieloma m\u00faltiplo reincidente \/ refrat\u00e1rio que receberam pelo menos 2 linhas de terapia anteriores incluindo lenalidomida e um inibidor [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/c1071005-mieloma-multiplo\\\/\",\"url\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/c1071005-mieloma-multiplo\\\/\",\"name\":\"C1071005 Mieloma m\u00faltiplo - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/#website\"},\"datePublished\":\"2022-10-24T21:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/c1071005-mieloma-multiplo\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/c1071005-mieloma-multiplo\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/c1071005-mieloma-multiplo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"C1071005 Mieloma m\u00faltiplo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/#website\",\"url\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rededorsaoluiz.com.br\\\/instituto\\\/idor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"C1071005 Mieloma m\u00faltiplo - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/","og_locale":"pt_BR","og_type":"article","og_title":"C1071005 Mieloma m\u00faltiplo - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"C1071005 Estudo de fase 3, randomizado, multic\u00eantrico, de 3 bra\u00e7os, aberto para avaliar a efic\u00e1cia e a seguran\u00e7a de monoterapia com elranatamabe (pf-06863135) e elranatamabe + daratumumabe versus daratumumabe + pomalidomida + dexametasona em participantes com mieloma m\u00faltiplo reincidente \/ refrat\u00e1rio que receberam pelo menos 2 linhas de terapia anteriores incluindo lenalidomida e um inibidor [&hellip;]","og_url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/","url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/","name":"C1071005 Mieloma m\u00faltiplo - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/#website"},"datePublished":"2022-10-24T21:02:13+00:00","breadcrumb":{"@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/c1071005-mieloma-multiplo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"C1071005 Mieloma m\u00faltiplo"}]},{"@type":"WebSite","@id":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/#website","url":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}